TC
ASMB icon

TFS Capital’s Assembly Biosciences ASMB Stock Holding History

TFS Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,038
Closed -$753K – 28
2017
Q2 		$753K Buy
+3,038
New +$856K 0.3% 112
2014
Q1 		– Sell
-3,611
Closed -$828K – 1342
2013
Q4 		$828K Buy
+3,611
New +$657K 0.04% 634
2013
Q3 		– Sell
-460
Closed -$66K – 1421
2013
Q2 		$66K Buy
+460
New +$72.1K ﹤0.01% 1450

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TFS Capital's ASMB Position: Q3 2017 in Review

TFS Capital sold out of Assembly Biosciences (ASMB) in Q3 2017, closing a stake of 3,038 shares — an estimated $753K sold.

TFS Capital first reported a position in ASMB in Q2 2013 and held it in 3 quarters. The position peaked at $828K in Q4 2013. 72 funds tracked by Wall St. Rank hold ASMB as of Q3 2017.

  • TFS Capital reported no remaining Assembly Biosciences position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 3,038 Assembly Biosciences shares in Q3 2017, an estimated $753K.
  • TFS Capital first reported a position in Assembly Biosciences in Q2 2013 and held it in 3 quarters.
  • TFS Capital's Assembly Biosciences position peaked at $828K in Q4 2013.
  • 72 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.